A Fornasiero Selected Research

Capecitabine (Xeloda)

11/2008

The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A Fornasiero Research Topics

Disease

2	Multiple Sclerosis 04/2015 - 01/2013
2	Rectal Neoplasms (Rectal Cancer) 10/2014 - 01/2000
1	Carcinoma (Carcinomatosis) 10/2014
1	Clinical Deterioration 01/2013
1	Colorectal Neoplasms (Colorectal Cancer) 11/2008
1	Neoplasms (Cancer) 01/2003
1	Thymoma (Thymic Carcinoma) 01/2003
1	Thymus Neoplasms (Thymus Neoplasm) 01/2003
1	Neutropenia 07/2001
1	Breast Neoplasms (Breast Cancer) 07/2001
1	Adenocarcinoma 01/2000

Drug/Important Bio-Agent (IBA)

1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2014
1	Natalizumab (Tysabri)FDA Link 01/2013
1	Capecitabine (Xeloda)FDA Link 11/2008
1	Fluorouracil (Carac)FDA LinkGeneric 11/2008
1	Ifosfamide FDA LinkGeneric 01/2003
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2003
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2001

Therapy/Procedure

4	Therapeutics 04/2015 - 01/2000
3	Drug Therapy (Chemotherapy) 01/2003 - 01/2000
1	Adjuvant Chemoradiotherapy 10/2014
1	Combination Drug Therapy (Combination Chemotherapy) 01/2003
1	Radiotherapy 01/2000